Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands |
3 Months Ended |
9 Months Ended |
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
| Condensed Consolidated Statements of Operations and Comprehensive Loss |
|
|
|
|
| Collaboration and other research and development revenues |
$ 962
|
$ 670
|
$ 5,155
|
$ 837
|
| Operating expenses: |
|
|
|
|
| Research and development |
10,832
|
3,850
|
30,144
|
13,020
|
| General and administrative |
11,295
|
4,202
|
33,215
|
10,756
|
| Total operating expenses |
22,127
|
8,052
|
63,359
|
23,776
|
| Operating loss |
(21,165)
|
(7,382)
|
(58,204)
|
(22,939)
|
| Other income (expense), net |
|
|
|
|
| Other income (expense), net |
3
|
21
|
(22)
|
(37,219)
|
| Interest income (expense), net |
142
|
(44)
|
419
|
(109)
|
| Total other income (expense), net |
145
|
(23)
|
397
|
(37,328)
|
| Net loss and comprehensive loss |
(21,020)
|
(7,405)
|
(57,807)
|
(60,267)
|
| Reconciliation of net loss to net loss attributable to common stockholders: |
|
|
|
|
| Net loss |
(21,020)
|
(7,405)
|
(57,807)
|
(60,267)
|
| Accretion of redeemable convertible preferred stock to redemption value |
|
(104)
|
(47)
|
(295)
|
| Net loss attributable to common stockholders |
$ (21,020)
|
$ (7,509)
|
$ (57,854)
|
$ (60,562)
|
| Net loss per share attributable to common stockholders, basic and diluted |
$ (0.59)
|
$ (2.57)
|
$ (1.86)
|
$ (25.53)
|
| Weighted-average common shares outstanding, basic and diluted |
35,505,429
|
2,925,843
|
31,040,670
|
2,371,976
|